Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ionis Pharmaceuticals's Enterprise Value for the quarter that ended in Jun. 2026 was MXN195,926 Mil.
Ionis Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was MXN-8,621 Mil. Ionis Pharmaceuticals's Earnings Yield (Joel Greenblatt) for the quarter that ended in Jun. 2026 was -3.57%.
The historical rank and industry rank for Ionis Pharmaceuticals's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
MEX:IONS'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -10.59 Med: -1.57 Max: 5.39
Current: -5.88
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Ionis Pharmaceuticals was 5.39%. The lowest was -10.59%. And the median was -1.57%.
MEX:IONS's Earnings Yield (Joel Greenblatt) % is ranked better than 58.98% of 1319
companies
in the Biotechnology industry
Industry Median: -10.06
vs MEX:IONS: -5.88
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Ionis Pharmaceuticals's Forward Rate of Return (Yacktman) % for the quarter that ended in Jun. 2026 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Ionis Pharmaceuticals Earnings Yield (Joel Greenblatt) % Related Terms
Ionis Pharmaceuticals Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Ionis Pharmaceuticals's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Ionis Pharmaceuticals's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ionis Pharmaceuticals Earnings Yield (Joel Greenblatt) % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ionis Pharmaceuticals's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Ionis Pharmaceuticals's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Ionis Pharmaceuticalss Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
Ionis Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-8,621 Mil.
What does a Earnings Yield (Joel Greenblatt) % of -3.57% mean?
Ionis Pharmaceuticals (MEX:IONS) has a Earnings Yield (Joel Greenblatt) % of -3.57% as of Jun. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Ionis Pharmaceuticals and its competitors. According to the industry distribution chart, Ionis Pharmaceuticals ranks #541 out of 1319 companies in the Biotechnology industry, placing it in the top 41%.
Is Ionis Pharmaceuticals' Earnings Yield (Joel Greenblatt) % too high?
Ionis Pharmaceuticals' current Earnings Yield (Joel Greenblatt) % is -3.57%. Based on the distribution chart, Ionis Pharmaceuticals ranks #541 out of 1319 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Ionis Pharmaceuticals has a GF Score™ of 71/100, reflecting its overall financial health beyond just this single metric.
How does Ionis Pharmaceuticals' Earnings Yield (Joel Greenblatt) % compare to KYMR and PRAX?
According to the Biotechnology industry distribution chart, Ionis Pharmaceuticals ranks #541 out of 1319 companies for Earnings Yield (Joel Greenblatt) %. This puts Ionis Pharmaceuticals in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Biotechnology company?
A good Earnings Yield (Joel Greenblatt) % depends on the Biotechnology industry context. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Ionis Pharmaceuticals and its competitors. Ionis Pharmaceuticals's current Earnings Yield (Joel Greenblatt) % is -3.57%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ionis Pharmaceuticals stock overvalued right now?
Ionis Pharmaceuticals (MEX:IONS) has a current Earnings Yield (Joel Greenblatt) % of -3.57%. The stock's GF Value™ is MXN1,061.81, compared to a current price of MXN1,150.00 — trading 8.3% above its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is -3.57%. Ionis Pharmaceuticals' overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Ionis Pharmaceuticals (MEX:IONS), the current Earnings Yield (Joel Greenblatt) % is -3.57% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ionis Pharmaceuticals (MEX:IONS) Overvalued in 2026?
Based on GuruFocus' analysis, Ionis Pharmaceuticals stock appears to be overvalued.
The current stock price of MXN1,150.00 is trading 8.3% above its estimated GF Value™ of MXN1,061.81.
Key valuation signals for MEX:IONS:
Earnings Yield (Joel Greenblatt) %: -3.57%
GF Value™: MXN1,061.81 vs. price of MXN1,150.00 (8.3% above fair value)
No single metric tells the full story. See the MEX:IONS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
71GF Score
Get the complete analysis for MEX:IONS
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:IONS has been successfully added to your 
